BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16307646)

  • 21. Germline splicing mutations of CDKN2A predispose to melanoma.
    Loo JC; Liu L; Hao A; Gao L; Agatep R; Shennan M; Summers A; Goldstein AM; Tucker MA; Deters C; Fusaro R; Blazer K; Weitzel J; Lassam N; Lynch H; Hogg D
    Oncogene; 2003 Sep; 22(41):6387-94. PubMed ID: 14508519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
    Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
    Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
    Goldstein AM
    Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
    Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
    Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
    Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
    Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
    Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
    Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation screening of the CDKN2A promoter in melanoma families.
    Harland M; Holland EA; Ghiorzo P; Mantelli M; Bianchi-Scarrà G; Goldstein AM; Tucker MA; Ponder BA; Mann GJ; Bishop DT; Newton Bishop J
    Genes Chromosomes Cancer; 2000 May; 28(1):45-57. PubMed ID: 10738302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.
    Rulyak SJ; Brentnall TA; Lynch HT; Austin MA
    Cancer; 2003 Aug; 98(4):798-804. PubMed ID: 12910525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
    Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
    Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
    BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.
    Rutter JL; Bromley CM; Goldstein AM; Elder DE; Holly EA; Guerry D; Hartge P; Struewing JP; Hogg D; Halpern A; Sagebiel RW; Tucker MA
    Cancer; 2004 Dec; 101(12):2809-16. PubMed ID: 15529312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
    Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
    Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
    Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families.
    Goldstein AM; Martinez M; Tucker MA; Demenais F
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):889-94. PubMed ID: 11008905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
    van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.